Amylyx Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Amylyx Pharmaceuticals

04/08/2026 13:45

Amylyx Pharmaceuticals Inc AMLX.OQ AMLX.O is expected to  show no change in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026

​LSEG's mean analyst estimate for Amylyx Pharmaceuticals Inc is for a loss of 36 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $22.00, about 9.1% above its last closing price of $20.17
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.37
-0.33
-0.37
Missed
-12
Dec. 31 2026
-0.36
-0.36
-0.30
Beat
16.4
Sep. 30 2025
-0.45
-0.45
-0.37
Beat
17.8​
Jun. 30 2025
-0.44
-0.45
-0.46
Missed
-3.3
​​Mar. 31 2025
-0.48
-0.47
-0.42
Beat
11.6
Dec. 31 2024
-0.52
-0.52
-0.55
Missed
-5.8​
Sep. 30 2024
-0.75
-0.71
-1.07
Missed
-50.7
Jun. 30 2024
-0.64
-0.73
-0.73
Met
0
This summary was machine generated August 4 at 12:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)